Result of AGM
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Result of AGM and Voting results
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The voting results of the AGM were as follows:
EKF Diagnostics Holdings plc
Mike Salter, CEO
Tel: +44 (0)29 2071 0570
Marc Davies, CFO
Singer Capital Markets (Nominated Adviser & Joint Broker)
Tel: +44 (0)20 7496 3000
Aubrey Powell / George Tzimas
Investec Bank plc (Joint Broker)
Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams / Ben Farrow
Walbrook PR Limited
Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Lianne Applegarth
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:
Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
Clinical chemistry, Small lab analysers, Centrifuges
Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
Enzyme fermentation, Custom products and Bulk fermentation
Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results.
EKF's growth strategy to 2024 and beyond can be summarised as:
continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships;
investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses;
expansion of CLIA Laboratories Testing offering, building on the acquired capabilities in ADL Health; and
identify complementary earnings-enhancing acquisitions with key strategic value.
EKF will also continue to generate enhanced shareholder value through:
a progressive dividend policy; and
its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health plc.